UW ’s Institute for Protein Design spinout raises $100M for vaccine development

Icosavax Inc., a life sciences spinout from the University of Washington, closed a $100 million Series B financing round, the biotech announced Wednesday. Icosavax, which was formed in 2018 after it emerged from the university’s Institute for Protein Design, makes vaccines using “self-assembling” virus-like particle technology developed at the institute, CEO Adam Simpson said. The company will use the money to support Icosavax’s clinical trials for its respiratory syncytial virus (RSV)…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news